Merck Gains Positive EU CHMP Opinion for KEYTRUDA and Padcev
RAHWAY, N.J. — September 18, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
PD-1 inhibitor
Advertisement
Harbour BioMed Partner Solstice Oncology Raises $225M
Shanghai, China, September 10, 2026 Solstice Oncology, a partner of Harbour BioMed, has announced a $225 million Series A...
FDA Approves Tudriqev for Advanced Refractory Melanoma
Silver Spring, Maryland, USA, August 8, 2026 The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
Genentech FDA Filing Advances Lunsumio-Polivy in LBCL
SOUTH SAN FRANCISCO, Calif., June 17, 2026 Genentech, a member of the Roche Group, has reached a significant regulatory...
Mabwell Showcases Strong 9MW2821 Cervical Cancer Data
COPENHAGEN, Denmark, June 18, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, has unveiled encouraging...
Advertisements
Regeneron Pharmaceuticals Melanoma Trial Misses Primary PFS Goal
TARRYTOWN, New York, May 15, 2026 Regeneron Pharmaceuticals announced updated results from its Phase 3 melanoma trial evaluating the...
LOQTORZI + Chemo Nearly Doubles Survival in NPC at Six Years
REDWOOD CITY, Calif., December 8, 2025 — Coherus Oncology today announced compelling six-year overall survival (OS) follow-up data from...
Junshi Biosciences Phase 3 Trial Confirms JS001sc Success in NSCLC
SHANGHAI, China, Nov. 25, 2025 — Junshi Biosciences announced that its Phase 3 clinical study evaluating JS001sc, a subcutaneous...
Advertisement
